News

Public · Published

AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry

Heartflow reported prospective outcomes from an evaluation of more than 6,000 well-matched patients in the DECIDE registry. At one year, plaque staging was associated with 34% fewer major cardiovascular events and half the heart-attack rate versus CCTA alone, alongside earlier improvement in patients reaching LDL-C goals.

Published:

Updated:

What happened

Heartflow reported prospective outcomes from an evaluation of more than 6,000 well-matched patients in the DECIDE registry. At one year, plaque staging was associated with 34% fewer major cardiovascular events and half the heart-attack rate versus CCTA alone, alongside earlier improvement in patients reaching LDL-C goals.

Confirmed

Global impact / market context

The reported link between plaque staging and better outcomes may support wider use of the tool and earlier treatment changes. If clinicians act on plaque measurements sooner, drug use and follow-up could increase, while preventing costly cardiovascular events could benefit patients and health providers.

Analyst inference

The article describes prospective registry findings, not evidence from a randomized trial, and says outcomes were associated with plaque staging compared with CCTA alone. The results therefore point to a possible care benefit, but do not establish that the tool itself caused fewer events.

Analyst inference

What to watch

  1. Whether the AHA presentation provides fuller details on study design, patient selection, follow-up, and event counts, which would help assess how broadly the results apply. Analyst inference
  2. Whether clinicians change prescribing or testing practices after seeing the findings; the article links plaque staging with earlier LDL-C goal achievement but does not report adoption. Analyst inference
  3. Whether subsequent studies confirm fewer cardiovascular events and heart attacks, since this registry comparison reports an association and cannot by itself prove the tool caused the difference. Analyst inference

Evidence